StageSeed
Raised$5.6M
Employees2
LocationSan Diego, CA
Business modelB2B, B2B2C, research collaborations (inferred via startup biotech model)
About
AivoCode is a neuroscience-focused biotech startup that is pioneering the development of innovative and broad platform technologies to improve the treatment and management of neurological diseases such as brain injury, Alzheimer’s disease and other neurodegenerative disorders.
Product
- Value proposition
- Developing broad platform technologies and therapeutic candidates to protect neurons, reduce neuroinflammation and oxidative stress, and preserve cognitive and motor function in brain injuries and neurodegenerative diseases.
- Target customers
- pharmaceutical/biotech companies, research institutions, and potential collaborators in neurodegenerative disease drug development
Founders
- Sajid Hussain (or Sazid Hussain) — Co-Founder & Chief Scientific Officer
- Erkki Ruoslahti — Co-Founder & Executive Chairman
- Aman Mann — Co-Founder & CEO
Categories
biotechneurodegenerative diseasesneurosciencedrug discoverytherapeutics
Products
therapeutic antibodies (targeting early AD vascular target)neuroprotective assetsplatform technologies for molecular zip codes screening
Key features
unbiased screening to identify molecular zip codes in diseased brain regionsearly intervention targets in Alzheimer’s diseaseneuroprotection and anti-inflammatory/antioxidant strategiestherapeutic antibodies development for neurodegenerative targetsbroad platform technologies for brain disease treatment
Technologies
unbiased screeningtherapeutic antibodiesneuroinflammation modulationneuroprotectionplatform technology for disease-region targeting
Target conditions
Alzheimer’s diseaseoptic neuropathiesglaucomaneuroinflammatory conditionsbrain injuriesneurodegenerative disorders
Care settings
research laboratory
Traction metrics
early-stage biotech startuplead candidate in neuroprotectionfocus on Alzheimer’s disease and optic neuropathies (Glaucoma)
Investors
National Science FoundationHHSSignite PartnersHana Financial GroupGGV CapitalSixteenth Street Capital
News
- AivoCode receives a $2.5M SBIR grant to develop a novel ... · 2026-04-06T00:00:00.000Z
- Researchers discover a compound that could change the treatment of traumatic brain injuries – IQAC – Institut de Química Avançada de Catalunya – CSIC · 2025-10-07T08:01:31.000Z
- Stem cells retain inflammatory memory, affecting regeneration and ... · 2025-09-19T00:00:00.000Z
- Todd Rubinstein's Post - LinkedIn · 2024-09-23T00:00:00.000Z
- Nucleate New York Returns to BlueRock for 4th Year - LinkedIn · 2026-04-24T00:00:00.000Z
Browse similar startups
Related startups
- Aizen Therapeutics — San Diego, CA
- Alcance Genomics LLC — San Diego, CA
- Alchemy — San Francisco, CA
- AllRx — Alhambra, CA
- Althea Health — San Jose, CA
- APEX CARDIOLOGY — Inglewood, CA
- Arialys Therapeutics — La Jolla, CA
- BlissGene Therapeutics Incorporated — Watertown, CT
- Duo Oncology — Pittsburgh, PA
- Entirety Biomedical — Newark
- Episteme Prognostics, Inc. — Brooklyn, NY
- Exactics, Inc. — Chicago, IL
Profile updated Jul 29, 2026. Sources: aivocode.com
